{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-324866","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2026-07-30T11:05:16+00:00","discovered_at":"2026-07-30T11:10:00.288625+00:00","generated_at":"2026-07-30T11:10:45.251563+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"EyePoint completes enrollment in both Phase 3 DME trials of DURAVYU; topline data Q4 2027","bullets":["Over 480 patients enrolled across COMO and CAPRI trials in five months, ahead of schedule.","Topline 56-week data for both DME trials anticipated in Q4 2027.","DSMC reviewed masked safety data in May 2026 and recommended continuation of both programs.","DURAVYU evaluated in over 190 patients across four completed trials with favorable safety profile.","Phase 3 program developed in alignment with FDA and EMA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-324866","json":"https://secwatch.observer/filing/0001193125-26-324866.json","markdown":"https://secwatch.observer/filing/0001193125-26-324866.md","text":"https://secwatch.observer/filing/0001193125-26-324866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526324866/0001193125-26-324866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526324866/eypt-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T11:10:45.251563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}